Despite significant scientific and clinical progress in the understanding and management of T2DM, patient care remains challenging. The approval of novel treatment options with improved safety, tolerability, and efficacy profiles (eg, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors) has expanded the therapeutic armamentarium for T2DM care. With this expanding array of agents, and the introduction of additional fixed-dose combinations, comes substantial challenges for physicians in selecting the most appropriate individualized regimen for their patients with T2DM.
Tina Vilsbøll, MD, DMSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck & Co., Inc.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck & Co., Inc.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Novo Nordisk
Stephen C. Bain, MD, MBBS, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Cellnovo; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk; Sanofi
Received grants for clinical research from: Novo Nordisk
Alice Y.Y. Cheng, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; SERVIER; Takeda Pharmaceuticals North America, Inc.; Valeant Pharmaceuticals International
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; Valeant Pharmaceuticals International
Stephan Matthaei, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk; Roche
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Omnia-Med; Roche
Received grants for clinical research from: Roche
Eduard Montanya, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Novo Nordisk
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novo Nordisk
Richard Pratley, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline; Hanmi Pharmaceuticals Co., Ltd.; Merck & Co., Inc.; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Novo Nordisk
Received grants for clinical research from: Eli Lilly and Company; Gilead Sciences, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.
Other: Received honoraria from: Novo Nordisk